Inventiva Interest Coverage from 2010 to 2025

IVA Stock  USD 2.82  0.14  4.73%   
Inventiva's Interest Coverage is increasing over the years with slightly volatile fluctuation. Interest Coverage is expected to dwindle to -18.58. From 2010 to 2025 Inventiva Interest Coverage quarterly data regression line had arithmetic mean of (6,333) and r-squared of  0.69. View All Fundamentals
 
Interest Coverage  
First Reported
2010-12-31
Previous Quarter
(17.69)
Current Value
(18.58)
Quarterly Volatility
8.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Inventiva financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inventiva's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 6.3 M or Selling General Administrative of 16.7 M, as well as many indicators such as Price To Sales Ratio of 9.25, Dividend Yield of 0.0 or Days Sales Outstanding of 268. Inventiva financial statements analysis is a perfect complement when working with Inventiva Valuation or Volatility modules.
  
Check out the analysis of Inventiva Correlation against competitors.

Latest Inventiva's Interest Coverage Growth Pattern

Below is the plot of the Interest Coverage of Inventiva Sa over the last few years. It is Inventiva's Interest Coverage historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inventiva's overall financial position and show how it may be relating to other accounts over time.
Interest Coverage10 Years Trend
Slightly volatile
   Interest Coverage   
-8.31K-450.27-19.78-80.78-19.66-17.69-18.58100%
       Timeline  

Inventiva Interest Coverage Regression Statistics

Arithmetic Mean(6,333)
Geometric Mean907.73
Coefficient Of Variation(131.49)
Mean Deviation6,975
Median(1,725)
Standard Deviation8,327
Sample Variance69.3M
Range19.8K
R-Value0.83
Mean Square Error22.8M
R-Squared0.69
Significance0.000063
Slope1,456
Total Sum of Squares1B

Inventiva Interest Coverage History

2025 -18.58
2024 -17.69
2023 -19.66
2022 -80.78
2021 -19.78
2019 -450.27
2018 -8313.25

About Inventiva Financial Statements

Inventiva stakeholders use historical fundamental indicators, such as Inventiva's Interest Coverage, to determine how well the company is positioned to perform in the future. Although Inventiva investors may analyze each financial statement separately, they are all interrelated. For example, changes in Inventiva's assets and liabilities are reflected in the revenues and expenses on Inventiva's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Inventiva Sa. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Interest Coverage(17.69)(18.58)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Inventiva Sa offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inventiva's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inventiva Sa Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inventiva Sa Stock:
Check out the analysis of Inventiva Correlation against competitors.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inventiva. If investors know Inventiva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inventiva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.14)
Revenue Per Share
0.383
Quarterly Revenue Growth
(0.59)
Return On Assets
(1.13)
Return On Equity
(16.43)
The market value of Inventiva Sa is measured differently than its book value, which is the value of Inventiva that is recorded on the company's balance sheet. Investors also form their own opinion of Inventiva's value that differs from its market value or its book value, called intrinsic value, which is Inventiva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inventiva's market value can be influenced by many factors that don't directly affect Inventiva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inventiva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inventiva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inventiva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

ELYM
ELYM Old
0.00  0.00  0.00 
VIGL
Vigil Neuroscience
2.42  -0.05  -2.02 
IMCR
Immunocore Holdings
29.37  -0.21  -0.71 
LIAN
LianBio ADR
0.00  0.00  0.00 
INBX
Inhibrx
13.25  0.65  5.16 
EWTX
Edgewise Therapeutics
26.17  -0.22  -0.83 
ANEB
Anebulo Pharmaceuticals
1.16  -0.04  -3.33 
CGEM
Cullinan Oncology LLC
8.49  -0.12  -1.39 
JANX
Janux Therapeutics
32.89  0.88  2.75 
VRCA
Verrica Pharmaceuticals
0.65  0.06  10.17 
DICE
Dice Molecules Holdings
0.00  0.00  0.00 
CMPX
Compass Therapeutics
2.90  -0.02  -0.68 
MLYS
Mineralys Therapeutics,
9.14  -0.82  -8.23 
PCVX
Vaxcyte
73.02  -1.2  -1.62 
HCWB
HCW Biologics
0.38  0.01  2.70 
IPHA
Innate Pharma
2.12  -0.04  -1.85 
RZLT
Rezolute
4.43  0.19  4.48 
ACLX
Arcellx
64.82  3.43  5.59 
VTYX
Ventyx Biosciences
1.58  0.13  8.97 
NAMS
NewAmsterdam Pharma
21.00  0.09  0.43 
News Freq…Investor S…